Pharmaceutical Market in Japan, Worth Just Under USD 70 Billion at the End of 2016, Will Cross USD 73 Billion by 2021
Japan is one of the biggest pharmaceutical markets in the world, and the industry is expected to keep growing at a moderate pace in the coming years. As the Japanese population grows older in comparison to other markets, the government has been responding to its aging population by easing several regulations and also introducing innovative new drugs into the market.
It is expected that the pharmaceutical market in Japan, worth just under USD 70 billion at the end of 2016, will cross USD 73 billion by 2021. In 2017, the Japanese market for active pharmaceutical ingredients (APIs) was one of the biggest in terms of revenues and had a share of nearly 55% of the global API industry. However, due to severe fluctuations in the Japanese currency against the US dollar as well as the high level of maturity evident in the Japanese pharmaceutical sector, it is expected that the market will grow at a slower than usual rate in the coming years.
This research analyzes the market for APIs in Japan in its research report Market for Active Pharmaceutical Ingredients in Japan – Forecast and Analysis 2018. The data covered in this report is from 2008 to 2020.
The report begins with an introduction to Active Pharmaceutical Ingredients and then moves on to briefly analyze the global market for active pharmaceutical ingredients. We include an overview of the global market for APIs and a look at the global market's revenues.
Section D of the report analyzes the market for active pharmaceutical ingredients in the Asia-Pacific region through an industry overview, industry revenues, and a look at the various therapeutic applications of APIs in the Asia-Pacific region. Impacts on the Asia Pacific active pharmaceutical ingredients market are also analyzed.
In section E, we begin our analysis of the market for active pharmaceutical ingredients in Japan. This section analyzes the industry through basic statistics and industry revenues. Industry segmentation through the biotech segment and the synthetic API market in Japan is included in the report, along with a forecast of the industry till 2020.
An analysis of the major industry players, both global and domestic, are included in the report. The major players are analyzed through a business segment profile, a look at their major products and services, and a SWOT analysis. The analysis looks at the top companies operating in the Japanese API market.
Research methodology for the report concludes this comprehensive report on the market for active pharmaceutical ingredients in Japan to 2020.
Table of Contents
A. Executive SummaryB. Introduction to Active Pharmaceutical Ingredients
Companies Mentioned
- Allergan Plc
- Aurobindo Pharma
- BASF SE
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd
- Daiichi Sankyo Company, Limited
- Dr. Reddy's Laboratories Limited
- Lupin Limited
- Medtronic Plc
- Mylan Inc
- Novartis AG
- Pfizer Inc.
- Ranbaxy Laboratories
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited